SCHEMBL6666027

SCHEMBL6666027

Clc1cccc(CNC2=NCCN2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 14/20 0.65
PTGIR P43119 1/20 0.59
LMNA P02545 2/20 0.48
ADRA2A P08913 2/20 0.48
ADRA2B P18089 2/20 0.48
ADRA2C P18825 2/20 0.48
ADRA1D P25100 2/20 0.48
ADRA1A P35348 2/20 0.48
ADRA1B P35368 2/20 0.48
MEN1 O00255 1/20 0.48
SLC22A1 O15245 1/20 0.48
SLC22A3 O75751 1/20 0.48
HTR1A P08908 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
HRH2 P25021 1/20 0.48
CYP2C19 P33261 1/20 0.48
OPRK1 P41145 1/20 0.48
KMT2A Q03164 1/20 0.48
HIF1A Q16665 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6666934 0.84 WDR5 (0.71) WDR5PTGIR
SCHEMBL13063072 0.82 WDR5 (0.55) WDR5PTGIRNISCH
SCHEMBL6300545 0.82 WDR5 (0.53) WDR5PTGIRLMNAADRA2AADRA2B
SCHEMBL17188814 0.82 WDR5 (0.56) WDR5PTGIRLMNA
SCHEMBL10800812 0.81 PTGIR (0.83) WDR5PTGIRADRA2AADRA2BADRA2C
SCHEMBL3169468 0.81 PTGIR (0.60) WDR5PTGIRLMNAADRA2AADRA2B
SCHEMBL8152769 0.81 WDR5 (0.69) WDR5PTGIRCYP2D6HIF1A
SCHEMBL21711673 0.80 WDR5 (1.00) WDR5
SCHEMBL21711783 0.80 WDR5 (1.00) WDR5
Iodide SCHEMBL3180056 0.79 WDR5 (0.67) WDR5PTGIRCYP2D6HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3496724-B1 PROTEIN KINASE REGULATORS NANJING GATOR MEDITECH COMPANY LTD (CN) 2021-10-06 EP disclosed
US-11091483-B2 Protein kinase regulators Madera Therapeutics, LLC (US) 2021-08-17 US disclosed
US-20190177323-A1 Protein Kinase Regulators Madera Therapeutics, LLC 2019-06-13 US disclosed
EP-1296958-A4 IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2004-01-28 EP disclosed
WO-2002000629-A9 IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2003-05-15 WO disclosed
EP-1296958-A1 IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2003-04-02 EP disclosed
US-6440976-B2 FOR THERAPY OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, STROKE, AND IN THERAPY OF NEUROPATHIES INCLUDING POSTHERPETIC NEURALGIA, CENTRAL PAIN FROM SPINAL CORD INJURY, AND PHANTOM LIMB PAIN MERCK & CO., INC. 2002-08-27 US disclosed
US-20020013329-A1 Iminopyrimidine NMDA NR2B receptor antagonists MERCK & CO., INC. 2002-01-31 US disclosed
WO-2002000629-A1 IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091483-B2 Protein kinase regulators MAP3K1, MAP3K6, MAP3K20 WDR5 3431/4885PTGIR 1868/4885LMNA 3613/4885
US-20190177323-A1 Protein Kinase Regulators MAP3K1, MAP3K6, MAP3K20 WDR5 3431/4885PTGIR 1868/4885LMNA 3613/4885
US-20020013329-A1 Iminopyrimidine NMDA NR2B receptor antagonists GRIN1, GRIN2B, GRIN2C WDR5 2268/4885PTGIR 887/4885LMNA 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.